Details of the Drug Reposition

General Information of This Drug (ID: DM7UF9M)

Drug Name
Omiganan   DM7UF9M
Synonyms CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial infection DIS5QJ9S 1A00-1C4Z Phase 3 [1]
Rosacea DIS02PWG ED90.0 Phase 3 [2]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
External genital and perianal wart DISMXE8S 1A95 Phase 2 [2]
Vulvar intraepithelial neoplasia DISA474V 2E67.10 Phase 2 [2]
Atopic dermatitis DISTCP41 EA80 Phase 2 [2]
Acne vulgaris DISKW8PI ED80 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00231153) Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)